Navigation Links
Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Date:11/23/2009

THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

The GASTRO 2009 meeting is a joint world conference in the area of gastroenterology. This meeting will bring together the world's leading organizations - the United European Gastroenterology Federation (UEGF), World Gastroenterology Organization (WGO), World Organization of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG) - for one of the biggest congresses in this area of medicine with more than 12,000 scientists from around the world expected to attend.

A summary of the GASTRO 2009 presentation (with audio) will be available on Lexicon's corporate website at www.lexpharma.com on November 25, 2009.

About LX1031

LX1031 is an orally available, locally acting inhibitor of tryptophan hydroxylase (TPH), an enzyme necessary for the biosynthesis of serotonin. LX1031 acts by selectively decreasing the production of serotonin in the gastrointestinal tract. Discovered and developed by Lexicon, LX1031 is t
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
2. Lexicon Announces Completion of Public Offering of Common Stock
3. Lexicon Announces Pricing of Common Stock in Public Offering
4. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
5. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... of the ResMed Data Exchange program, a comprehensive ... medical equipment (HME) and other health care providers. ... secure access to critical patient information. It integrates ... AirView™ and U-Sleep™ patient management platforms with customers, ...
(Date:10/20/2014)... PRINCETON, N.J. , Oct. 20, 2014 /PRNewswire/ ... Taiho Pharmaceutical Co., Ltd. ( Japan ... Administration (FDA) granted Fast Track designation for TAS-102 ... combination anticancer drug under investigation for the treatment ... the Company has initiated a rolling NDA submission ...
(Date:10/20/2014)... October 20, 2014 Norgine B.V. ... novel, low volume bowel preparation, NER1006, presented at the ... College of Gastroenterology (ACG), Philadelphia, PA ... stool weight and co-primary endpoint of cleansing success. The ... vs. MOVIPREP ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will ... Tuesday, February 15, 2011.  The presentation is scheduled for ... through the Company,s web site, www.regeneron.com , on ... presentation will be available after the live webcast through ...
... Feb. 8, 2011 IPC The Hospitalist Company, Inc. (Nasdaq: ... practice company, announced today that it will report results for ... Monday, March 7, 2011, after the market close. ... 5:00 p.m. ET (2:00 p.m. PT) on March 7, 2011 ...
Cached Medicine Technology:IPC The Hospitalist Company, Inc. to Report Fourth Quarter 2010 Results 2
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, ... of Columbus, Inc., A Division of MaternOhio Clinical Associates, ... than 100,000 patients annually. Dr. Murphy will provide a ... of a women’s life. She is accepting new patients ... and Dublin. , Dr. Murphy offers a wide variety ...
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... , CHADDS FORD, Pa., Aug. 31 Endo Pharmaceuticals (Nasdaq: ... Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. ... and development programs. , , The presentation will be webcast ... under the investors section. , , ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... is over-treatment for many men, researchers say , MONDAY, Aug. ... a test for prostate-specific antigen (PSA) has led to mass ... PSA screening test came into use in 1986, federal government ... the United States has risen substantially, said the report in ...
... 31 (HealthDay News) -- Walk-in retail clinics staffed by nurse ... has found. , Writing in the Sept. 1 issue of ... Ateev Mehrotra said that retail clinics -- which are typically ... other retail chain stores such as Target and Wal-Mart -- ...
... , , ABBOTT PARK, Ill., Aug. ... the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, ... financial officer, will make a presentation on the company at 8:10 ... webcast of the presentation will be accessible through Abbott,s Investor Relations ...
... as fires threaten , , WASHINGTON, Aug. 31 ... evacuees a safe place to stay as wildfires in California force people ... took refuge from the smoke and fire in Red Cross shelters. ... , "If you are ordered to leave your home, please ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Prostate Cancer Over-Diagnosed: Study 2Health News:Prostate Cancer Over-Diagnosed: Study 3Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3
... Farnsworth panel D15 test evaluation has ... to arrange caps with automatic creation ... manual color deficiency analysis, calculation of ... age-corrected CCI, eye selection (OD, OS, ...
... test is used to separate ... vs normal. Farnsworth D15 come ... the patient to select the ... box is closed and the ...
HRR/Amsler book combo with occluding glasses....
Ishihara test chart book for color blindness. 14 plate. A simple accurate method for discovering congenital color blindness....
Medicine Products: